(-0.12%) 5 462.55 points
(-0.08%) 39 080 points
(0.11%) 17 737 points
(-0.63%) $80.32
(-4.32%) $2.64
(-0.77%) $2 312.80
(0.13%) $28.91
(2.33%) $1 009.40
(0.31%) $0.936
(0.72%) $10.68
(0.47%) $0.792
(-0.16%) $87.35
Live Chart Being Loaded With Signals
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company\'s pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia...
Stats | |
---|---|
Today's Volume | 31 931 |
Average Volume | 35 256 |
Market Cap | 19.53M |
EPS | $-0.660 ( Q3 | 2023-11-06 ) |
Last Dividend | $1 801.73 ( 1980-05-12 ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.270 (7.58%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-26 | Devall Christopher Franklin | Buy | 7 000 | Common Stock |
2023-12-26 | Wool Kyle Michael | Buy | 5 000 | Common Stock |
2023-12-21 | Wool Kyle Michael | Buy | 630 050 | Common Stock |
2023-12-20 | Hayes Anthony | Buy | 70 000 | Common Stock |
2023-12-12 | Hayes Anthony | Buy | 2 000 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 6 932 818 | Sell: 0 |
Volume Correlation
AIkido Pharma Inc. Correlation
10 Most Positive Correlations | |
---|---|
GNACW | 0.901 |
10 Most Negative Correlations | |
---|---|
DAOO | -0.958 |
GNAC | -0.946 |
IIII | -0.935 |
SHQA | -0.911 |
SCOA | -0.905 |
HCIC | -0.901 |
HCII | -0.894 |
HIIIU | -0.883 |
HCICU | -0.851 |
HIII | -0.847 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
AIkido Pharma Inc. Correlation - Currency/Commodity
AIkido Pharma Inc. Financials
Annual | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-5.60 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-5.60 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-4.34 |
FY | 2020 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-7.47 |
Financial Reports:
No articles found.
AIkido Pharma Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $1 544.34 | 1978-05-15 |
Last Dividend | $1 801.73 | 1980-05-12 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $5 147.79 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.53 | -- |
Div. Sustainability Score | 1.053 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
1978 | $0 | 0.00% |
1979 | $0 | 0.00% |
1980 | $0 | 0.00% |
1981 | $0 | 0.00% |
1982 | $0 | 0.00% |
1983 | $0 | 0.00% |
1984 | $0 | 0.00% |
1985 | $0 | 0.00% |
1986 | $0 | 0.00% |
1987 | $0 | 0.00% |
1988 | $0 | 0.00% |
1989 | $0 | 0.00% |
1990 | $0 | 0.00% |
1991 | $0 | 0.00% |
1992 | $0 | 0.00% |
1993 | $0 | 0.00% |
1994 | $0 | 0.00% |
1995 | $0 | 0.00% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
12 May 1980 | $1 801.73 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
14 May 1979 | $1 801.73 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
15 May 1978 | $1 544.34 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -19.43 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.318 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.306 | 1.500 | -4.51 | -6.76 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 20.26 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 16.48 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.55 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00650 | -1.500 | 9.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 36.16 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -3.04 | 2.00 | -1.012 | -2.02 | [0 - 30] |
freeCashFlowPerShareTTM | -3.10 | 2.00 | -1.552 | -3.10 | [0 - 20] |
debtEquityRatioTTM | 0.00704 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 1.000 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -23.01 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -39.50 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0164 | 0.800 | -3.22 | -2.58 | [0.5 - 2] |
Total Score | 1.053 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.947 | 1.000 | -0.197 | 0 | [1 - 100] |
returnOnEquityTTM | -0.306 | 2.50 | -2.90 | -6.76 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -3.10 | 2.00 | -1.035 | -3.10 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -3.04 | 2.00 | -1.012 | -2.02 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0144 | 1.500 | -3.43 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -15.70 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.67 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company\'s pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators